Progression‐free survival · people with advanced gastric cancer
Taxane‐platinum‐fluoropyrimidine combinations probably leads to lower progression‐free survival compared with taxane‐platinum (without fluoropyrimidine) (moderate certainty).
1 finding from 1 review
Treatment‐related death · people with advanced gastric cancer
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment‐related death compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment discontinuation due to toxicity compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
1 finding from 1 review
All‐cause infant mortality at longest · HIV‐positive pregnant women co‐infected with hepatitis B virus
It is very uncertain whether tenofovir‐based antiviral combination regimens changes all‐cause infant mortality at longest compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
1 finding from 1 review
Proportion of infants with serious adverse events ( · HIV‐positive pregnant women co‐infected with hepatitis B virus
It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of infants with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
1 finding from 1 review
Proportion of infants with HBV mother‐to‐child transmission · HIV‐positive pregnant women co‐infected with hepatitis B virus
1 finding from 1 review
Maternal death · HIV‐positive pregnant women co‐infected with hepatitis B virus
1 finding from 1 review
Proportion of mothers with serious adverse events ( · HIV‐positive pregnant women co‐infected with hepatitis B virus
It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of mothers with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
1 finding from 1 review
Proportion of participants who were drop‐free · open‐angle glaucoma
It is very uncertain whether IStent in combination with phacoemulsification changes proportion of participants who were drop‐free compared with phacoemulsification alone (very low certainty).
1 finding from 1 review
Mean change in number of IOP‐lowering drops from baseline · open‐angle glaucoma
1 finding from 1 review
Difference in mean IOP from baseline at < 6 months · open‐angle glaucoma
1 finding from 1 review
Health‐related quality of life · open‐angle glaucoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intraoperative complications · open‐angle glaucoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Postoperative complications · open‐angle glaucoma
1 finding from 1 review
Secondary glaucoma surgery · open‐angle glaucoma
1 finding from 1 review
Stress symptoms ( · healthcare workers
3 findings from 1 review
no estimate extracted
15 studies · 1003 participants
Low
no estimate extracted
6 studies · 574 participants
Low
no estimate extracted
1 study · 88 participants
Very low
Length of hospital stay · children hospitalised with an acute asthma exacerbation
1 finding from 1 review
Time to regular dose of short‐acting beta2‐agonists (hours) · children hospitalised with an acute asthma exacerbation
1 finding from 1 review
Asthma clinical scores · children hospitalised with an acute asthma exacerbation
Combination of anticholinergics + beta2‐agonists showed no clear difference in asthma clinical scores compared with beta2‐agonists alone (moderate certainty).
1 finding from 1 review
Incidence of admissions to the ICU · children hospitalised with an acute asthma exacerbation
1 finding from 1 review